Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tafamidis
Drug ID BADD_D02107
Description Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Indications and Usage Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.[A189708,A189711,L11280]
Marketing Status approved; investigational
ATC Code N07XX08
DrugBank ID DB11644
KEGG ID D09673
MeSH ID C547076
PubChem ID 11001318
TTD Drug ID D04DFR
NDC Product Code 60715-0647; 59651-743; 66039-960; 73435-031; 14501-0102; 58159-079; 60715-4344; 0069-8730; 11014-0390; 69988-0039
UNII 8FG9H9D31J
Synonyms tafamidis | Vyndamax | Vyndaqel | FX 1006A | FX1006A | FX-1006A | tafamidis meglumine
Chemical Information
Molecular Formula C14H7Cl2NO3
CAS Registry Number 594839-88-0
SMILES C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.013297%
Abdominal pain upper07.01.05.003--
Ageusia17.02.07.001; 07.14.03.0030.002746%Not Available
Amyloidosis10.02.05.0010.004845%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.001077%
Aortic stenosis24.04.01.0010.001346%Not Available
Aortic valve stenosis02.07.03.0040.000808%Not Available
Arrhythmia02.03.02.0010.003607%Not Available
Arrhythmia supraventricular02.03.03.0010.000538%Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.001884%Not Available
Arthralgia15.01.02.0010.016904%
Arthritis15.01.01.0010.006999%
Arthropathy15.01.01.0030.003176%Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.001615%
Asthenia08.01.01.0010.020188%Not Available
Atelectasis22.01.02.0010.000808%
Atrial fibrillation02.03.03.0020.024979%
Atrial flutter02.03.03.0030.005653%
Atrioventricular block02.03.01.0020.001884%Not Available
Atrioventricular block complete02.03.01.0030.001346%
Atrioventricular block second degree02.03.01.0050.001615%
Auditory disorder04.02.03.0020.000538%Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.000808%Not Available
Back pain15.03.04.0050.014535%
Basal cell carcinoma23.08.02.001; 16.03.02.0010.000538%Not Available
Benign prostatic hyperplasia21.04.02.0010.003230%Not Available
Bradycardia02.03.02.0020.004038%Not Available
Bundle branch block left02.03.01.0070.001346%Not Available
Bundle branch block right02.03.01.0110.001077%Not Available
Cardiac amyloidosis02.04.01.013; 10.02.05.0020.017227%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages